• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

56.93 -0.31 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Peering Into Vaxcyte's Recent Short Interest ↗
October 30, 2024
 
Via Benzinga
News headline image
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 06, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
September 04, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Peering Into Vaxcyte's Recent Short Interest ↗
August 27, 2024
 
Via Benzinga
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
September 03, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
September 03, 2024
 
Via Benzinga
News headline image
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 ↗
May 08, 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Recap: Vaxcyte Q4 Earnings ↗
February 27, 2024
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗
September 03, 2024
 
Via Benzinga
News headline image
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher ↗
September 03, 2024
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
News headline image
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market ↗
September 03, 2024
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
News headline image
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 03, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints John Furey to Board of Directors
July 02, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says ↗
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
News headline image
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
March 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap